27.2±0.1°, 27.7±0.1°, 28.8±0.1°, and 29.6±0.1°.

[0017] Further, the X-ray powder diffraction pattern of the crystalline form M represented by an angle of 2θ is shown in FIG. 5.

[0018] Further, TGA and DSC patterns of the crystalline form M are shown in FIG. 6.

[0019] The present disclosure further provides a method for preparing the crystalline form M of the compound 1, the method including the steps of:

(1) adding the compound 1 to an alcohol solvent and heating at a temperature ranging from 75°C to 80°C to dissolve the compound 1;

(2) stirring at a temperature ranging from 10°C to 30°C to precipitate crystals; and

(3) filtering and drying the crystals to obtain an off-white solid, i.e., the crystalline form M.

[0020] Preferably, the alcohol solvent is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, n-pentanol, tert-pentanol or a mixed solvent containing ethanol; preferably, the mixed solvent containing ethanol is selected from tetrahydrofuran/water/ethanol, tetrahydrofuran/ethanol, or DMF/ethanol.

[0021] In the present disclosure, an X-ray powder diffraction pattern of the crystalline form F represented by an angle of 2θ has diffraction peaks at 7.1±0.1°, 8.0±0.1°, 10.0±0.1°, 10.9±0.1°, 14.0±0.1°, 15.4±0.1°, 16.0±0.1°, 16.5±0.1°, 17.1±0.1°, 19.5±0.1°, 22.0±0.1°, 25.0±0.1°, and 28.1±0.1°.

[0022] Further, the X-ray powder diffraction pattern of the crystalline form F represented by an angle of 2θ has diffraction peaks at 7.1±0.1°, 8.0±0.1°, 9.0±0.1°, 10.0±0.1°, 10.9±0.1°, 11.3±0.1°, 14.0±0.1°, 15.4±0.1°, 16.0±0.1°, 16.5±0.1°, 17.1±0.1°, 18.0±0.1°, 19.5±0.1°, 19.8±0.1°, 20.4±0.1°, 21.4±0.1°, 22.0±0.1°, 22.8±0.1°, 24.4±0.1°, 25.0±0.1°, 26.2±0.1°, 27.7±0.1°, 28.1±0.1°, 29.6±0.1°, and 33.5±0.1°.

[0023] Further, the X-ray powder diffraction pattern of the crystalline form F represented by an angle of 2θ is shown in FIG. 7.

[0024] Further, TGA and DSC patterns of the crystalline form F are shown in FIG. 8.

[0025] The present disclosure further provides a method for preparing the crystalline form F of a compound 1, the method including steps of:

crystalline form F of the compound 1

[00103] Drug samples of different crystalline forms of the compound 1 were added to a solution of 1% CMC-Na respectively to prepare suspensions, which were administrated to mice by gavage. Drug samples of the different crystalline forms of the compound 1 were prepared into solutions in DMSO/PEG400/water and administered intravenously to mice. After drug administration, blood samples were collected from the dorsal vein of foot at different time points. After anticoagulation with heparin sodium, plasma was extracted by centrifugation. Plasma samples were analyzed by LC-MS/MS to obtain plasma drug concentrations. Pharmacokinetic parameters were calculated by WinNonlin (Phoenix^{TM}). The results of the bioavailability analysis for the crystalline form AB, the crystalline form M, and the crystalline form F are presented in Table 6.

[00104] Table 6

Crystalline form		$T_{1/2}$	T_{max}	C_{max}	AUC_{last}	AUC_{Inf}	$AUC_{_\%Extrap}$	MRT	AUC_{last}/D	F (0→t) (1036+1622)	F (0→∞) (1036+1622)
		h	h	ng/mL	h*ng/mL	h*ng/mL	%	h	h*mg/mL	%	%
M	Mean	3.61	0.917	200	581	1110	39	5.65	58.1	13.6(9.1-18.5)	14
	Standard Deviation	2.11	0.585	79	223	694	30.2	2.88	22.3	3.6	3.6
AB	Mean	0.86	1.33	930	2399	2414	1.19	1.91	240	43.1(26.2-61.8)	43.2
	Standard Deviation	0.11	0.75	427	899	881	2.3	0.37	90	49.8	49.9
F	Mean	1.7	1.5	201	505	675	22.7	3.05	50.5	9.6(5.9-19)	9.7
	Standard Deviation	1.05	0.77	45	82	162	16.9	1.32	8.2	5.7	5.9

[00105] The results in Table 6 show that the plasma exposure and bioavailability of the crystalline form AB are higher than those of the crystalline M and the crystalline form F. In this regard, the crystalline form AB appears to be more promising for clinical use.

[00106] The present disclosure has been disclosed in the preferred embodiments above, which are not intended to limit the claims. Any person skilled in the art could make several possible variations and modifications without departing from the concept of the present disclosure, and therefore the protection scope of the present disclosure shall be set forth by the claims of the present disclosure.